AB50 - Congenital Hearing Loss: Complete ICD-11 Coding Guide

1. Introduction

Congenital hearing loss represents one of the most prevalent sensory conditions at birth, significantly affecting language development, communication, and social integration in children. This condition is characterized by hearing loss present at birth or developed during the prelingual period, before the child has acquired basic spoken language skills.

The clinical importance of congenital hearing loss transcends the purely audiological aspect. The critical period for language acquisition occurs in the first years of life, and unidentified or untreated hearing loss during this phase can result in permanent delays in cognitive, educational, and social development. Studies demonstrate that early identification and appropriate intervention before six months of age can result in language development comparable to that of hearing children.

From a public health perspective, universal neonatal hearing screening has become a priority in various health systems globally. Early detection allows for timely interventions, including hearing device fitting, cochlear implants when indicated, and support for language development through specialized therapies.

Correct coding of congenital hearing loss is critical for multiple reasons: it enables appropriate epidemiological tracking, facilitates resource planning in public health, ensures appropriate access to specialized services, and assures precise documentation for reimbursement purposes and longitudinal follow-up. The code AB50 in ICD-11 was specifically designated to capture this condition accurately and differentiate it from other forms of hearing loss.

2. Correct ICD-11 Code

Code: AB50

Description: Congenital hearing impairment

Parent category: Disorders with hearing impairment

Official definition: Congenital hearing impairment is characterized by hearing loss present before language acquisition, occurring due to a congenital condition. This category encompasses both genetic and non-genetic causes of congenital deafness. There are dominant and recessive genes that can cause hearing damage ranging from mild to profound. When a family has a dominant gene for deafness, it will persist across generations because it will manifest in offspring even if inherited from only one parent. If genetic hearing impairment is caused by a recessive gene, it will not always be apparent, as it must be transmitted to children by both parents.

Code AB50 is used specifically for cases where hearing loss is present at birth or develops in the early neonatal period, before the child has developed spoken language. This code encompasses both syndromic and non-syndromic forms of congenital deafness, regardless of the specific etiology, as long as the hearing loss is of congenital origin.

3. When to Use This Code

The code AB50 should be applied in specific clinical scenarios where hearing impairment is clearly established as congenital. Below, we present detailed practical situations:

Scenario 1: Newborn with bilateral failure in neonatal hearing screening A 48-hour-old infant fails neonatal hearing screening by otoacoustic emissions in both ears. Subsequent evaluation with auditory brainstem response (ABR) at 30 days confirms bilateral profound sensorineural hearing loss. Family history reveals that the parents are first-degree cousins, suggesting possible autosomal recessive inheritance. There is no history of congenital infections, exposure to ototoxic medications, or other acquired risk factors. Code AB50 is appropriate because hearing loss is present from birth and has a congenital origin.

Scenario 2: Infant with genetic syndrome associated with deafness A 3-month-old child is diagnosed with Pendred syndrome following investigation of congenital hypothyroidism. Audiological evaluation reveals bilateral moderate to severe sensorineural hearing loss. Imaging studies show Mondini malformation. In this case, although a specific syndrome exists, code AB50 is used to document congenital hearing impairment and may be complemented with additional codes for the specific syndrome.

Scenario 3: Child with family history of hereditary deafness A 2-month-old infant, child of deaf parents who use sign language, undergoes audiological evaluation confirming bilateral profound sensorineural deafness. Family history reveals an autosomal dominant pattern of nonsyndromic deafness through three generations. Genetic testing identifies a mutation in the GJB2 gene (connexin 26). Code AB50 is applicable because it documents the congenital and hereditary nature of the condition.

Scenario 4: Neonate with congenital malformation of the inner ear A child is born with bilateral atresia of the external auditory canal identified on neonatal physical examination. Imaging studies by computed tomography and magnetic resonance imaging reveal malformations of the middle and inner ear. Audiological evaluation confirms bilateral severe conductive hearing loss. Because the malformation and resulting hearing loss are congenital, code AB50 is appropriate.

Scenario 5: Infant with deafness identified before 6 months without acquired risk factors A 4-month-old child is brought for evaluation because parents noticed absence of response to sounds. History reveals pregnancy and delivery without complications, no congenital infections, no use of ototoxic medications, and normal neonatal metabolic screening. Audiological evaluation confirms bilateral moderate sensorineural hearing loss. Although the specific etiology is not identified, the absence of acquired factors and presence in the prelingual period justify code AB50.

Scenario 6: Child with congenital infection and subsequent deafness A newborn diagnosed with congenital cytomegalovirus (CMV) infection through urine PCR in the first two weeks of life develops bilateral progressive sensorineural hearing loss identified at 3 months of age. Although the infection is acquired in utero, the resulting deafness is considered congenital because it is present before language acquisition and results from a congenital condition. Code AB50 is appropriate, complemented by the specific code for congenital CMV infection.

4. When NOT to Use This Code

It is fundamental to distinguish situations where code AB50 should not be applied, avoiding coding errors:

Hearing loss acquired after birth: If a child is born with normal hearing, confirmed by newborn screening, and subsequently develops hearing loss due to bacterial meningitis at 18 months of age, the appropriate code is AB51 (Acquired hearing impairment), not AB50, even if the loss occurs in the prelingual period.

Noise-induced hearing loss in adolescents: Adolescents or young adults who develop hearing loss due to chronic exposure to elevated noise levels (loud music, industrial environments) should be coded with AB51, as the loss is clearly acquired and not congenital.

Age-related hearing loss: Presbycusis or age-related hearing loss should be coded as AB51, not AB50, regardless of family history of deafness.

Ototoxic hearing loss: When hearing loss results directly from the use of ototoxic medications such as aminoglycosides, platinum-based chemotherapy agents, or other drugs known to cause cochlear damage, the appropriate code is AB53 (Ototoxic hearing loss). This applies even when exposure occurs in the neonatal period, as the cause is iatrogenic and not congenital.

Deafness of undetermined etiology in adults: When an adult presents with hearing loss of unknown cause without clear evidence of congenital origin or history suggestive of prelingual onset, the most appropriate code is AB52 (Deafness, unspecified).

Impacted cerumen or otitis media with effusion: Conditions that cause temporary and reversible conductive hearing loss should not be coded as AB50, but rather with specific codes for the underlying otological condition.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

Confirmation of congenital hearing loss diagnosis requires a systematic and multidisciplinary approach. The first step is to establish the presence of hearing loss through objective methods appropriate for age.

In newborns and young infants, evoked otoacoustic emissions and auditory brainstem evoked potential are the gold standard instruments. Otoacoustic emissions assess the function of outer hair cells of the cochlea, while ABEP assesses the integrity of auditory pathways from the cochlea to the brainstem. In older children who can cooperate, behavioral audiometry and subsequently pure-tone threshold audiometry provide detailed information about hearing thresholds at different frequencies.

Etiological investigation should include detailed gestational history (maternal infections, teratogen exposure, medications), family history of deafness (inheritance patterns, consanguinity), complete physical examination seeking dysmorphisms or signs of genetic syndromes, and complementary tests such as imaging studies (computed tomography of temporal bones, magnetic resonance imaging of inner ears), testing for congenital infections (TORCH), and genetic evaluation when indicated.

Step 2: Verify specifiers

ICD-11 allows specification of important characteristics of congenital hearing loss. Severity should be documented according to audiometric thresholds: mild (26-40 dB), moderate (41-60 dB), severe (61-80 dB), or profound (>80 dB). Laterality (unilateral or bilateral) is crucial, as it has different implications for language development and intervention strategies.

The type of hearing loss should also be specified: sensorineural (cochlear or retrocochlear damage), conductive (problem in external or middle ear), or mixed (sensorineural and conductive components). The presence or absence of progression should be documented when known, as some forms of genetic congenital deafness are progressive.

If the specific etiology is known (syndromic genetic, non-syndromic genetic, congenital malformation, congenital infection), this should be documented through appropriate additional codes that complement AB50.

Step 3: Differentiate from other codes

AB51 - Acquired hearing loss: The fundamental difference is the timing and cause of onset. AB51 is used when hearing loss develops after birth due to acquired causes such as postnatal infections (meningitis, chronic otitis media), acoustic trauma, head trauma, or autoimmune diseases. Even if hearing loss occurs in the prelingual age, if the cause is clearly acquired after a period of normal hearing, AB51 is the correct code.

AB52 - Hearing loss, unspecified: This code is used when there is documented hearing loss, but there is insufficient information to determine whether the origin is congenital or acquired, or when the etiology remains undetermined after appropriate investigation. AB52 serves as a "residual" code when specific criteria for AB50 or AB51 cannot be established.

AB53 - Ototoxic hearing loss: This specific code is reserved for cases where there is a clear causal relationship between exposure to ototoxic agents and development of hearing loss. Medications such as aminoglycosides, vancomycin, cisplatin, and furosemide in high doses are common causes. Even when administered in the neonatal period, if hearing loss is attributed to medication toxicity and not to a pre-existing congenital condition, AB53 is more appropriate than AB50.

Step 4: Required documentation

Adequate documentation is essential to justify AB50 coding. The medical record should contain:

Checklist of mandatory information:

• Results of neonatal hearing screening with dates and methods used
• Complete diagnostic audiological evaluation with type, degree, and configuration of hearing loss
• Detailed gestational and perinatal history
• Family history of hearing loss with inheritance patterns when applicable
• Complete physical examination with attention to dysmorphisms or syndromic signs
• Results of etiological investigation (imaging, genetic testing, serology for congenital infections)
• Exclusion of acquired causes of hearing loss
• Documentation of age of identification of hearing loss
• Intervention and follow-up plan

The record should clearly establish that hearing loss was present at birth or developed before language acquisition due to a congenital condition, differentiating it from acquired causes.

6. Complete Practical Example

Clinical Case:

Sofia is a girl who was born via normal vaginal delivery at term, without gestational or perinatal complications. Sofia's mother, Ana, is 28 years old and is a second-degree cousin of the father, João, who is 30 years old. There was no exposure to teratogenic medications during pregnancy, and prenatal screening for infections was negative.

At 2 days of life, Sofia underwent universal neonatal hearing screening through evoked otoacoustic emissions, failing bilaterally. The test was repeated after 15 days with the same result. Sofia was then referred for specialized audiological evaluation.

At 45 days of life, Sofia underwent auditory brainstem evoked potential under sedation, which revealed absence of reproducible waves bilaterally up to 90 dB nHL, consistent with bilateral profound sensorineural hearing loss. Pediatric physical examination was normal, without dysmorphisms or other syndromic findings. Family history revealed that a paternal aunt of João is also deaf since birth, and the paternal grandparents are first-degree cousins.

Complementary investigation included magnetic resonance imaging of the inner ears, which showed anatomically normal cochleae and auditory nerves. Serological tests for congenital cytomegalovirus, toxoplasmosis, rubella, and syphilis were negative. Expanded metabolic screening was normal. Ophthalmological and cardiological evaluation revealed no abnormalities.

At 3 months, Sofia was referred for genetic counseling. Analysis of the GJB2 gene (connexin 26) revealed homozygous mutation c.35delG, confirming nonsyndromic genetic deafness with autosomal recessive inheritance. Sofia initiated hearing rehabilitation with hearing aids at 4 months and was referred for evaluation for bilateral cochlear implant.

Step-by-Step Coding:

Criteria analysis:

1. Presence of hearing loss confirmed by objective methods (ABEP)
2. Hearing loss present at birth (failure in neonatal screening)
3. Identified congenital cause (GJB2 genetic mutation)
4. Absence of acquired factors (no infections, no ototoxics, no trauma)
5. Identification in the pre-lingual period (before 6 months)

Code selected: AB50 - Congenital hearing impairment

Complete justification: Code AB50 is the most appropriate for Sofia's case because all criteria for congenital hearing impairment are present. Hearing loss was identified in the neonatal period through universal screening, confirmed by objective diagnostic evaluation (ABEP), and etiological investigation established a congenital genetic cause (GJB2 mutation). Family history with autosomal recessive inheritance pattern and parental consanguinity reinforce the hereditary nature of the condition. There is no evidence of acquired causes such as congenital infections, ototoxic exposure, or trauma. Early identification and initiation of intervention before 6 months of age are consistent with the management protocol for congenital hearing impairment.

Applicable complementary codes:

• Specific code for nonsyndromic deafness related to GJB2 (if available in the genetic coding system)
• Codes for procedures: hearing aid fitting, evaluation for cochlear implant
• Codes for multidisciplinary follow-up: speech-language pathology, otorhinolaryngology, genetics

7. Related Codes and Differentiation

Within the Same Category:

AB51: Acquired hearing impairment

When to use AB51 vs. AB50: AB51 should be used when hearing loss develops after birth due to acquired causes, even if it occurs in the prelingual period. Examples include hearing loss secondary to bacterial meningitis, chronic otitis media with complications, head trauma, or exposure to intense noise. The fundamental difference is that in AB51 the child is born with normal hearing (documented by neonatal screening) and subsequently develops hearing loss, whereas in AB50 the loss is present from birth.

Main difference: The temporal and etiological distinction. AB50 = congenital origin, present at birth; AB51 = acquired origin, develops after a period of normal hearing.

AB52: Deafness, unspecified

When to use AB52 vs. AB50: AB52 is applied when there is documented hearing loss, but insufficient information to determine whether the origin is congenital or acquired. Common situations include adult patients without detailed medical history available, cases where etiological investigation was not performed or was inconclusive, or when there is no documentation of the onset of hearing loss. AB52 serves as a residual category.

Main difference: AB50 requires clear documentation of congenital origin; AB52 is used when this determination cannot be made with certainty.

AB53: Ototoxic hearing loss

When to use AB53 vs. AB50: AB53 is specific for hearing losses caused by exposure to ototoxic medications or substances. Even when exposure occurs in the neonatal period (for example, gentamicin treatment for neonatal sepsis), if there is a clear causal relationship between the medication and hearing loss, AB53 is more appropriate. The distinction is important because ototoxicity is potentially preventable and has medico-legal implications.

Main difference: AB53 identifies a specific iatrogenic cause (medications/toxins); AB50 refers to congenital causes (genetic, malformations, intrauterine infections).

Differential Diagnoses:

Auditory maturation delay: Some children may fail neonatal screening due to delay in maturation of auditory pathways, not due to permanent hearing loss. Serial evaluations show normalization of hearing thresholds. Should not be coded as AB50.

Auditory neuropathy/auditory dyssynchrony: A condition where outer hair cells function normally (otoacoustic emissions present), but there is dysfunction of neural transmission (abnormal ABR). It may be congenital or acquired and requires specific coding when available, supplemented by AB50 if the origin is congenital.

Temporary conductive hearing loss: Conditions such as neonatal otitis media with effusion or obstruction of the ear canal by vernix may cause screening failure, but are reversible and should not be coded as AB50.

8. Differences with ICD-10

In ICD-10, congenital hearing loss was coded primarily under H90.3 (Bilateral sensorineural hearing loss) or H90.5 (Unspecified sensorineural hearing loss) when the sensorineural nature was known, or under more specific codes in Q16 (Congenital malformations of the ear causing hearing impairment) when there were anatomical malformations. There was no specific code that captured the comprehensive concept of "congenital hearing loss" regardless of mechanism.

ICD-11 introduces code AB50 as a distinct category that encompasses all forms of hearing loss of congenital origin, whether genetic, malformative, or related to congenital infections. This change better reflects modern understanding of the importance of distinguishing congenital hearing loss from acquired loss, particularly in the context of universal newborn screening programs and early intervention.

Major changes in ICD-11:

• Creation of specific category for congenital hearing loss (AB50)
• Clear separation between congenital (AB50) and acquired (AB51) hearing loss
• Better alignment with newborn screening protocols
• Facilitates epidemiological tracking of congenital vs. acquired causes
• Allows complementary coding with specific etiological codes

Practical impact: The change facilitates identification of cases that would benefit from early intervention, improves planning of newborn screening programs, and allows better understanding of the epidemiology of congenital versus acquired deafness in different populations.

9. Frequently Asked Questions

1. How is congenital hearing loss diagnosed?

Diagnosis begins with universal newborn hearing screening, ideally performed within the first 48 hours of life, using evoked otoacoustic emissions or automated auditory brainstem response. Newborns who fail the initial screening are retested after 15-30 days. Those who fail the retest are referred for complete diagnostic audiological evaluation, which should include diagnostic ABR to determine hearing thresholds and locate the site of lesion. Subsequent etiological investigation may include imaging studies (magnetic resonance imaging or computed tomography of temporal bones), genetic testing, evaluation for congenital infections, and detailed physical examination seeking signs of associated syndromes. Definitive diagnosis requires confirmation of hearing loss through objective methods and determination that the loss was present at birth or has a congenital origin.

2. Is treatment available in public health systems?

The availability of treatment for congenital hearing loss varies considerably among different health systems and geographic regions. Many public health systems offer universal newborn screening programs, diagnostic evaluation, and fitting of hearing aids. The availability of more advanced technologies such as cochlear implants may be more limited in some settings, with specific eligibility criteria and waiting lists. Auditory rehabilitation services, including specialized speech-language pathology therapy, are essential components of treatment, and their availability also varies. Families should be guided to seek specific information about resources available in their local health systems, including possibilities for coverage by private health insurance when applicable.

3. How long does treatment last?

The management of congenital hearing loss is a longitudinal process that extends throughout childhood and often into adulthood. Initial intervention with hearing devices (hearing aids or implants) should ideally occur before 6 months of age to optimize language development. Intensive auditory rehabilitation, including speech-language pathology therapy, is generally necessary during the first years of life, with session frequency gradually decreasing as the child develops communication skills. Regular audiological follow-up is necessary throughout childhood to adjust devices, monitor progression of hearing loss, and evaluate language development. Many individuals with congenital hearing loss require ongoing support during school age and device adjustments throughout life. "Treatment" does not have a defined endpoint, but evolves into a model of follow-up and support as needs change with age.

4. Can this code be used in medical certificates?

Yes, code AB50 can and should be used in medical certificates when appropriate. Documentation of congenital hearing loss through proper coding is important for various purposes, including access to special education services, requesting hearing devices and assistive technologies, justification for academic or professional accommodations, and documentation for social benefits purposes when applicable. Medical certificates should include not only the ICD code, but also clear description of the type and degree of hearing loss, laterality, hearing devices in use, and functional impact. It is important that health professionals provide complete and accurate documentation that allows families to access the necessary resources and supports to optimize the child's development and quality of life.

5. Is congenital hearing loss always genetic?

No, although genetic causes are responsible for a significant proportion of congenital hearing loss cases, there are other important etiologies. Congenital infections, particularly cytomegalovirus, toxoplasmosis, and rubella, can cause congenital deafness. Congenital malformations of the external, middle, or inner ear may occur in isolation or as part of syndromes. Intrauterine exposure to certain medications or toxins can result in hearing damage. In many cases, despite comprehensive investigation, the specific cause remains unidentified. Identification of the etiology is important for family counseling regarding recurrence, identification of associated syndromic manifestations requiring follow-up, and prognosis, but does not necessarily change code AB50, which is applicable regardless of the specific cause, as long as the hearing loss is of congenital origin.

6. Can children with congenital hearing loss develop spoken language?

Yes, with early identification and appropriate intervention, many children with congenital hearing loss can develop functional spoken language. Outcomes depend on multiple factors, including the degree of hearing loss, age of identification and intervention, quality and consistency of hearing device use, intensity of auditory rehabilitation, and family involvement. Children with mild to moderate losses generally develop spoken language with appropriate hearing aids and therapy. Children with severe to profound losses may benefit from cochlear implants, especially when performed before 18-24 months of age, with many achieving spoken language abilities comparable to hearing peers. It is important to recognize that sign language is also a valid and complete linguistic option, and many families choose bilingual approaches that include both spoken language and sign language.

7. Can congenital hearing loss worsen over time?

Some forms of congenital hearing loss are stable, while others are progressive. Certain genetic conditions, such as some mutations in specific genes or particular syndromes, are associated with progressive hearing loss. Congenital infections, especially cytomegalovirus, may result in hearing loss that progresses during childhood. Malformations such as enlarged vestibular aqueduct may be associated with fluctuations or progression of hearing loss, sometimes triggered by minor head trauma. For these reasons, all children with congenital hearing loss should have regular audiological follow-up throughout childhood, with frequency determined by the specific etiology and stability of the hearing loss. Early identification of progression allows timely adjustments in amplification and intervention strategies.

8. What is the difference between congenital hearing loss and prelingual deafness?

The terms are related but not synonymous. "Congenital hearing loss" refers specifically to the origin of hearing loss—present at birth or due to a congenital condition. "Prelingual deafness" refers to the timing of hearing loss in relation to language development—loss that occurs before the acquisition of spoken language, typically before 2-3 years of age. Most cases of congenital hearing loss are prelingual, as it is present from birth. However, it is possible to have prelingual deafness that is not congenital (for example, hearing loss due to meningitis at 18 months), or theoretically to have a congenital condition that does not manifest as hearing loss until after language acquisition (although this is rare). Code AB50 is specific to congenital origin, regardless of when hearing loss is identified, as long as it is related to a condition present at birth.

---

Keywords: ICD-11, AB50, congenital hearing loss, congenital deafness, newborn hearing screening, genetic hearing loss, medical coding, deafness diagnosis, cochlear implant, auditory rehabilitation

External References

This article was prepared based on reliable scientific sources:

1. 🌍 WHO ICD-11 - Congenital hearing impairment
2. 🔬 PubMed Research on Congenital hearing impairment
3. 🌍 WHO Health Topics
4. 📊 Clinical Evidence: Congenital hearing impairment
5. 📋 Ministry of Health - Brazil
6. 📊 Cochrane Systematic Reviews

References verified on 2026-02-03